nach oben

Current Oncology Reports

Erschienen in:

01.03.2018 | Palliative Medicine (A Jatoi, Section Editor)

Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors

verfasst von: Lisa A. Kottschade

Erschienen in: Current Oncology Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The unleashing of the immune system in an effort to fight cancer has proven to be an incredible advance in the war on cancer. However that breakthrough has come with a price in the form of serious and potentially fatal immune-related adverse events (irAEs).

Recent Findings

Rapid recognition and early intervention is imperative to avoid significant morbidity and mortality. Additionally, providers need to be aware that there are still new, rare, and long-term emerging irAEs that were not previously reported in clinical trials.

Summary

Because of the significant difference between irAEs and those caused by chemotherapy and/or targeted therapy, providers must have a thorough understanding of which events would be considered immune related and require treatment. This review will cover descriptions of the most common and uncommon but serious irAEs experienced by patients on immunotherapy, as well as management of these irAEs.

Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;312(17):1744–53. https://doi.org/10.1001/jama.2014.13943.PubMedCentralCrossRefPubMed

Hodi FS, O’Day SJ, DF MD, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.PubMedCentralCrossRefPubMed

McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056–64. https://doi.org/10.1016/j.ctrv.2014.06.012.CrossRefPubMed

Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300–9. https://doi.org/10.1158/078-0432.CCR-13-143. CrossRefPubMed

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82. https://doi.org/10.1200/JCO.2014.59.4358.PubMedCentralCrossRefPubMed

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093.CrossRefPubMed

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. https://doi.org/10.1056/NEJMoa1104621.CrossRefPubMed

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–22. https://doi.org/10.1200/JCO.2012.44.6112.PubMedCentralCrossRefPubMed

• Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;JCO2016721167. Largest pooled analysis to date of irAEs from combination ICI therapy.

10.

• Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. Large review and meta-analysis of irAEs from anti-CTLA-4 therapy. PubMedCentralCrossRefPubMed

11.

Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. https://doi.org/10.1016/j.ctrv.2016.02.003.CrossRefPubMed

12.

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/NEJMoa1504627.PubMedCentralCrossRefPubMed

13.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. https://doi.org/10.1056/NEJMoa1200694.PubMedCentralCrossRefPubMed

14.

Co. M. Keytruda (pembrolizumab) for injection: Highlights of Prescribing Information. 2014, Accessed April 19, 2015 at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.

15.

Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297–306. https://doi.org/10.1007/s00262-008-0642-y.CrossRefPubMed

16.

Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, et al., editors. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma 2011. J Clin Oncol. 2011.

17.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.PubMedCentralCrossRefPubMed

18.

Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33(8):665–80. https://doi.org/10.1016/j.ctrv.2007.06.004.CrossRefPubMed

19.

Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–92. https://doi.org/10.18632/oncotarget.2980.PubMedCentralCrossRefPubMed

20.

Mier JW. Checkpoint inhibitors in the treatment of metastatic melanoma. Clin Ther. 2015;37(4):753.CrossRefPubMed

21.

O’Day S, Weber JS, Wolchok JD, Richards JM, Lorigan P, McDermott DF, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol. 2011; 29(15_suppl):8554.

22.

O’Sullivan CG, Madan RA, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol. 2014;32(10):986–8. https://doi.org/10.1200/JCO.2013.54.5996.CrossRef

23.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17. https://doi.org/10.1056/NEJMoa1414428.PubMedCentralCrossRefPubMed

24.

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62. https://doi.org/10.1038/nature13904.CrossRefPubMed

25.

Rivere A, Bourgeois DJ, Riker AI. Use of ipilimumab in melanoma. Immunotherapy. 2011;3(8):927–30. https://doi.org/10.2217/imt.11.77. CrossRefPubMed

26.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMoa1412082.CrossRefPubMed

27.

Robert C, Schadendorf D, Messina M, Hodi FS, O’Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19(8):2232–9. https://doi.org/10.1158/078-0432.CCR-12-3080.CrossRefPubMed

28.

Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27(6):478–9. https://doi.org/10.1097/00002371-200411000-00008.CrossRefPubMed

29.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. https://doi.org/10.1056/NEJMoa1302369.PubMedCentralCrossRefPubMed

30.

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. https://doi.org/10.1016/S470-2045(09)70334-1.CrossRefPubMed

31.

Zibelman M, Olszanski AJ. Full spectrum: efficacy and toxicity of immunotherapy in metastatic melanoma. J Natl Compr Cancer Netw. 2014; 12(suppl. 2): S-1–S-5.

32.

• Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17(4):387–94. Good overview of ocular toxicities which is a rare irAE. CrossRefPubMed

33.

Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 2009;32(3):322–4. https://doi.org/10.1097/CJI.0b013e31819aa40b.CrossRefPubMed

34.

Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest. 2013;143(3):858–61. https://doi.org/10.1378/chest.12-467. CrossRefPubMed

35.

Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30(17):e156–9. https://doi.org/10.1200/JCO.2011.39.3298.CrossRefPubMed

36.

Bompaire F, Mateus C, Taillia H, De Greslan T, Lahutte M, Sallansonnet-Froment M, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30(6):2407–10. https://doi.org/10.1007/s10637-011-9787-1.CrossRef

37.

Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–80. https://doi.org/10.1136/practneurol-2012-000447.CrossRefPubMed

38.

Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–75. https://doi.org/10.1210/jc.2012-4075.CrossRefPubMed

39.

Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med. 2011;365(18):1747–8. https://doi.org/10.1056/NEJMc1110923. CrossRefPubMed

40.

Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211–2. https://doi.org/10.1056/NEJMc0904283.CrossRefPubMed

41.

Gonzalez-Rodriguez E, Rodriguez-Abreu D. Spanish Group for Cancer I-B. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21(7):804–16. https://doi.org/10.1634/theoncologist.2015-0509.PubMedCentralCrossRefPubMed

42.

Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009;58(8):1351–3. https://doi.org/10.1007/s00262-008-0627-x.CrossRefPubMed

43.

Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2017:1. https://doi.org/10.1097/COC.0000000000000374.

44.

Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009;36(4):518–20. https://doi.org/10.1017/S0317167100007939.CrossRefPubMed

45.

Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32(4):769–73. https://doi.org/10.1007/s10637-014-0092-7.CrossRef

46.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013;1(6):373–7. https://doi.org/10.1158/2326-6066.CIR-13-0092.PubMedCentralCrossRefPubMed

47.

Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs. 2013;31(4):1071–7. https://doi.org/10.1007/s10637-013-9939-6.CrossRef

48.

Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93. https://doi.org/10.1093/neuonc/nou001.PubMedCentralCrossRefPubMed

49.

Lozier J. More on hemophilia A induced by ipilimumab. N Engl J Med. 2012;366(3):280–1; author reply 1. https://doi.org/10.1056/NEJMc1113863#SA1.PubMed

50.

Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012;30(6):e76–8. https://doi.org/10.1200/JCO.2011.38.7886.CrossRefPubMed

51.

Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–6. https://doi.org/10.1056/NEJMc1302338. CrossRefPubMed

52.

• Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–81. Comprehensive review of endocrine toxicities from ICI therapy. This is an often difficult irAE to diagnose and manage and this article does a good job of defining these toxicities. PubMedCentralCrossRefPubMed

53.

Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–9. https://doi.org/10.1200/JCO.2005.04.5716.PubMedCentralCrossRefPubMed

54.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. https://doi.org/10.1056/NEJMoa1305133.PubMedCentralCrossRefPubMed

55.

• Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016;26(5):469–80. Good comprehensive overview with algorithms of a multidisciplinary approach to manage irAEs for ICI therapy. CrossRefPubMed

56.

Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712–7. https://doi.org/10.1073/pnas.0830997100.PubMedCentralCrossRefPubMed

57.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. https://doi.org/10.1056/NEJMoa1200690.PubMedCentralCrossRefPubMed

58.

Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–82. https://doi.org/10.1002/cncr.27969.CrossRefPubMed

59.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9. https://doi.org/10.1056/NEJMoa1412690.CrossRefPubMed

60.

Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–3. https://doi.org/10.1093/annonc/mdr028.CrossRefPubMed

61.

Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin Gastroenterol Hepatol. 2007;5(1):70–4. https://doi.org/10.1016/j.cgh.2006.09.035.CrossRefPubMed

62.

Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017;66(1):25–32. https://doi.org/10.1007/s00262-016-1913-7.CrossRefPubMed

63.

Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I. Case report: pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy. 2017;9(10):797–804. https://doi.org/10.2217/imt-2017-0042.CrossRefPubMed

64.

Telo GH, Carvalhal GF, CGS C, Webber VS, Barrios CH, Fay AP. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Ann Oncol. 2017;28(1):191–2. https://doi.org/10.1093/annonc/mdw447.PubMed

Titel: Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
verfasst von: Lisa A. Kottschade
Publikationsdatum: 01.03.2018
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 3/2018
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-018-0671-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Exercise Training and Cardiovascular Health in Cancer Patients

Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients

Melanoma and Immune Checkpoint Inhibitors

Electronic Assessment of Physical Decline in Geriatric Cancer Patients

Mucosal Melanoma: a Literature Review

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie